Mesoblast (NasdaqGS:MESO) 2025 Earnings Call Presentation

Global Leader in Allogeneic Cellular Medicines for Inflammatory Diseases Annual General Meeting 2025 November 2025 ASX: MSB; Nasdaq: MESO For personal use only To be the world's leading and most innovative cell therapy company, commercializing off-the-shelf allogeneic cellular medicines to treat serious and life-threatening inflammatory illnesses 3 Our Mission Execution Strategy For personal use only CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS This presentation includes forward-looking statements a ...